Nelson Royall, MD FACS

Hepato-Pancreato-Biliary Surgery, Northeast Georgia Health System, Gainesville, GA

[Alvaro Arjona @alarjosan]

@GarciaOlmoD @VillarejoCampos @DrSGlezMoreno @h_guadalajara Adj HIPEC with Ox during 30 minutes did not improve the Recurrence Free Survival in COLOPEC trial, however adjuvant HIPEC with MMC improved the locoregional control rate at 3 y in HIPECT4 trial. https://t.co/8A7WfwKB1b

[Kevin El-Hayek, MD, MBA, FACS @KevinElHayekMD]

Happy to share our work from @metrohealthCLE (FREE download from @SurgJournal until December 23!) on #MALS.

For MALS surgeons out there, are you routinely performing a ganglionectomy and lymphadenectomy?

@jamiepdecicco @fnuraja @MalsNational https://t.co/vQJPcSp4Xv

[Marc Besselink @MarcBesselink]

Today: #CAMINO trial #CRLM published in @TheLancetOncol; great team effort with @EAHPBA surgeons & radiologists from 14 centers 🇳🇱🇳🇴🇮🇹🇧🇪

✅#MRI changes clinical management in 32% of 298 patients scheduled for #surgery / #ablation of #colorectal #livermetastases based on CT only.

✅Results confirmed by “blinded” expert panel.

https://t.co/laH9Q47uDR

[Arndt Vogel @ArndtVogel]

🔥of the press: Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing
@OncologyAdvance
Cancer Treatment Reviews
https://t.co/iSsffcsvvr
👉GA are actionable in 30–50% of CCAs
👉we provide practical advice on NGS use & a detailed overview of frequently used NGS tests
@myESMO @EASLnews @ILCAnews @curecc #livertwitter

[Arndt Vogel @ArndtVogel]

Effect of HIPEC on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: GASTRIPEC-I Phase III
@JCO_ASCO
https://t.co/brY7mRFyQj
❓to do or not to do
👉HIPEC improves PFS, but not OS
👉Subgroup may benefit more, PCI ≥7
🧐Debate continues..
@myESMO

[Yakup Ergün @dr_yakupergun]

#ESMO23
MATTERHORN study: Perioperative durvalumab+FLOT in gastric/GEJ cancer

Durvalumab vs Placebo
pCR➡️19.0% vs 7.0%✅
R0 resection➡️similar (86%)

Presented by. Dr. Salah-Eddin Al-Batran

@myESMO @oncodaily @VJOncology @Oncoinfo_it @OncoAlert

[Marc Besselink @MarcBesselink]

Should pts w/ #idiopathic #pancreatitis undergo EUS? How often #surgery 🔪 required?

#PICUS trial: 105 pts IAP, 24 centers 🇳🇱; EUS found a cause in 32%; biliary (24%) - #cholecystectomy, chronic pancreatitis (7%), and neoplasm (3%) - #pancreatoduodenectomy

IAP recurrence in 1-year:
17% with negative EUS ❌
6% with positive EUS ✅

➡️https://t.co/ZGQzL9JRug

[Giovanni Marchegiani @Gio_Marchegiani]

The first ever Radiomics 👾 preoperative fistula risk score !!!

Development 🇳🇱 and external validation 🇮🇹

🐳 The radiomics-based preop FRS performed similarly to the existing scores ( ROC 0.8)

💪 Great added value considering only CT derived data!

https://t.co/E6Brd9WDhv

[Arndt Vogel @ArndtVogel]

🔥off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC
@JAMAOnc
https://t.co/NtFWGjHMff
👉ORR: 14.3% vs 5.4%
👉mOS: 15.9 vs 14.1mo
🧐non-inferiority, in line with Nivo & Durva, but we need a "niche" or a biomarker...
@myESMO @EASLedu @ILCAnews #livertwitter

[Thor Halfdanarson @OncoThor]

We know that the risk of small intestinal NETs (siNETs) is increased among 1st degree relatives - I am following a few families. This GWAS study identified 4 novel risk loci for small intestinal NETs including a missense mutation in LGR5. Very interesting

https://t.co/uUyqVCbtBX

[Alejandro Rosales @HpbNicaragua]

Outcomes of pancreatic cancer with liver oligometastasis - Takeda - 2023 - Journal of Hepato-Biliary-Pancreatic Sciences - Wiley Online Library https://t.co/pDIxMYe0rt

[Arndt Vogel @ArndtVogel]

Phase I/IIa Trial of Yttrium-90 Radioembolization in
Combination with Durvalumab for HCC
@CCR_AACR
10.1158/1078-0432.CCR-23-0581
🔎🇰🇷, 24pts
👉mOS n.r.; mPFS 6.9 mo
👉CR: 29.2%, PR: 54.2%
👉clinically feasible & encouraging efficacy
@myESMO @EASLedu @ILCAnews #livertwitter

[Syed A. Ahmad @SyedAAhmad5]

Important paper. Can ChatGTP give patients the wrong information. Study finds nearly a third of recs were not concordant with NCCN guidelines. Garbage in ➡️ garbage out. We saw this during Covid. ⁦@JAMAOnc⁩ ⁦@SWOG⁩ ⁦@DavendraSohal⁩ https://t.co/S3u98c3Nj3

[Journal of the American College of Surgeons (JACS) @acsJACS]

The role of adjuvant chemotherapy (AC) in patients with ampullary adenocarcinoma (AA) remains controversial. This study aimed to determine if AC improve the prognosis of patients with resected AA.

Read at: https://t.co/B1s1ju3Z5y

[Nelson Royall, MD FACS @nelsonroyall]

Great overview of role of #surgery in #PancreasCancer with metastases. Limited data and need trials initiated to guide decisions ⁦@AHPBA⁩ ⁦@IHPBA⁩ https://t.co/9hVuu7z15I

[Pierre Gholam @pgholam]

Fatty Liver= #SLD
#NAFLD= #MASLD
#NASH=#MASH
#MASLD who drink ethanol > 140 g F or 210 g M weekly= #MetALD
Alcohol related liver disease= #ALD
SLD with known cause (drug, Wilson, other genetic etc…) = specific etiology SLD
SLD without known metabolic or other risk= cryptogenic SLD

[Dr. Cathy Eng @CathyEngMD]

JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS. https://t.co/uFRInZDMZx
Just a joy to work with @adasarimd @MDAndersonNews @hutchmed @TakedaOncology. @VUMCDiscoveries @VUMC_Cancer #crcsm #CancerResearch

[Annals of Surgical Oncology @AnnSurgOncol]

CA19-9 Response to First-Line #Neoadjuvant #FOLFIRINOX and Second-Line #Gemcitabine / #NabPaclitaxel for Patients with Operable #PancreaticCancer @SamThaljiMD @isteaus @MCWSurgery @MedicalCollege
https://t.co/OC0LGmDHfp #VisualAbstract

[Nelson Royall, MD FACS @nelsonroyall]

@erin_schumer @WashU_CT @WashUSurgery @AmitPawaleMD @MFarazMasood @KunalKotkarMD @UofL_cts @UofLHealth @uofl Congrats!

[Giovanni Marchegiani @Gio_Marchegiani]

Drainage of large walled off pancreatic necroses 🥎 a RCT from 🇩🇰

EUS guided Plastic 🤜🤛 LAMS

🟰 technical success (95 / 100%); adverse events and length of stay

🤔 for large WON are LAMS not superior?! Want to hear comments from my endo friends!

https://t.co/pZU9x5B6fU